You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Lung Cancer Screening and Early Detection

  • Authors: Lecia V. Sequist, MD, MPH; Efrén J. Flores, MD; Ray U. Osarogiagbon, MBBS; Terri Ann DiJulio
  • CME / ABIM MOC / CE Released: 4/1/2022
  • Valid for credit through: 4/1/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    Nurses - 0.75 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)

    IPCE - 0.75 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, radiologists, surgeons, primary care physicians, critical care specialists, internal medicine specialists, emergency medicine physicians, nurses/nurse practitioners, physician assistants, and pharmacists involved in the care of patients with or at risk for lung cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or malignant pleural mesothelioma (MPM).

The goal of this activity is that learners will be better able to discuss the spectrum of lung cancer and provide strategies that can help translate data updates to improvements in patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Importance of improving early lung cancer detection and screening
    • Clinical study data evaluating screening and early detection methods
  • Demonstrate greater confidence in their ability to
    • Incorporate strategies into clinical practice that may improve early detection of lung cancer, as part of the interprofessional team 
    • Identify optimal approaches to patient care


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


  • Lecia V. Sequist, MD, MPH

    The Landry Family Professor of Medicine
    Harvard Medical School
    Director, Center for Innovations in Early Cancer Detection
    Massachusetts General Hospital
    Boston, Massachusetts


    Disclosure: Lecia V. Sequist, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Genentech; Janssen; Pfizer; Takeda
    Research funding from: AstraZeneca; Boehringer Ingelheim; Genentech; Novartis

  • Efrén J. Flores, MD

    Associate Chair, Equity, Inclusion & Community Health
    MGB Enterprise Radiology
    Assistant Professor of Radiology
    Harvard Medical School
    Radiologist, Thoracic Division
    Massachusetts General Hospital
    Scholar in Diagnostic Excellence
    National Academy of Medicine
    The Mongan Institute
    Health Promotion & Resiliency Intervention Research
    Boston, Massachusetts


    Disclosure: Efrén J. Flores, MD, has no relevant financial relationships.

  • Raymond U. Osarogiagbon, MBBS

    Chief Scientist  
    Baptist Memorial Health Care Corporation  
    Memphis, Tennessee 


    Disclosure: Raymond U. Osarogiagbon, MBBS, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Eli Lilly; Genentech Roche; Triptych Healthcare Partners
    Speaker or member of speakers bureau for: Biodesix
    Royalties from: Patented Lymph node Specimen Kit
    Stock options from: Eli Lilly; Gilead Sciences; Pfizer
    Ownership interest: Oncobox Device, Inc (ended December, 2021)

  • Terri Ann DiJulio

    Lung Cancer Survivor 
    Patient Advocate 
    West Chester, Pennsylvania 


    Disclosure: Terri Ann DiJulio, has no relevant financial relationships.


  • Deborah Grainger, PhD

    Medical Education Director, WebMD Global, LLC


    Disclosure: Deborah Grainger, PhD, has no relevant financial relationships.

  • John Churchwell, PhD

    Medical Education Director, Medscape, LLC


    John Churchwell, PhD, has the following relevant financial relationships:
    Employed by an ineligible company: Medtronic (ended 2021)

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) (Universal Activity Number: JA0007105-0000-22-094-H01-P)

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Lung Cancer Screening and Early Detection

Authors: Lecia V. Sequist, MD, MPH; Efrén J. Flores, MD; Ray U. Osarogiagbon, MBBS; Terri Ann DiJulioFaculty and Disclosures

CME / ABIM MOC / CE Released: 4/1/2022

Valid for credit through: 4/1/2023


Contents of This CME Activity

All sections of this activity are required for credit.

Barriers and Opportunities to Advance Equity in Lung Cancer Screening

Watch Dr Flores discuss barriers and opportunities in advancing equity for lung cancer screening.
Efrén J. Flores, MD

Incidental Pulmonary Nodules: Uncharted Territory?

Dr Osarogiagbon explores uncharted territory in incidental pulmonary nodules.
Ray U. Osarogiagbon, MBBS

Liquid Biopsies in Early Detection of Lung Cancer

Learn more about liquid biopsies in early detection of lung cancer in this presentation led by Dr Sequist.
Lecia V. Sequist, MD, MPH

Assessment Survey

Before you begin, please take this brief survey.

  • Print